1 |
Brechot C (2004). Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology, 127, S56-61.
DOI
ScienceOn
|
2 |
Chan HL, Hui AY, Wong ML, et al (2004).Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut, 53, 1494-98.
DOI
ScienceOn
|
3 |
Cho EY, Choi CS, Cho JH, et al (2011).Association between Hepatitis B Virus X Gene Mutations and Clinical Status in Patients with Chronic Hepatitis B Infection. Gut Liver, 5, 70-76.
DOI
ScienceOn
|
4 |
Choi CS, Cho EY, Park R, et al (2009). X gene mutations in hepatitis B patients with cirrhosis, with and without hepatocellular carcinoma. J Med Virol, 81, 1721-5.
DOI
ScienceOn
|
5 |
Chu CM,(2002).Precore stop mutant in anti-HBe-positive phases of chronic hepatitis B virus infection. Am J Gastroenterol,97, 2138-9.
|
6 |
Cong YS, Yao YL, Yang WM, et al (1997). The hepatitis B virus X-associated protein, XAP3, is a protein kinase Cbinding protein. J Biol Chem, 272, 16482-9.
DOI
ScienceOn
|
7 |
Fang ZL, Sabin CA, Dong BQ, et al (2008). HBV A1762T, G1764A mutations are a valuable biomarker for identifying a subset of male HBsAg carriers at extremely high risk of hepatocellular carcinoma: a prospective study. Am J Gastroenterol, 103, 2254-62.
DOI
ScienceOn
|
8 |
Ferlay J, Shin HR, Bray F, et al (2010).Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-17.
DOI
ScienceOn
|
9 |
Guo X, Jin Y, Qian G, et al (2008). Sequential accumulation of the mutations in core promoter of hepatitis B virus is associated with the development of hepatocellular carcinoma in Qidong, China. J Hepatol, 49, 718-25.
DOI
ScienceOn
|
10 |
Ja KK, Hye YC, Jung ML, et al (2009). Specific mutations in the enhancer II/core promoter/precore regions of hepatitis B virus subgenotype C2 in Korean patients with hepatocellular carcinoma. J Med Virol, 81, 1002-8.
DOI
ScienceOn
|
11 |
Jang JW, Chun JY, Park YM, et al (2012). Mutational complex genotype of the hepatitis B virus X/precore regions as a novel predictive marker for hepatocellular carcinoma. Cancer Sci, 103, 296-304.
DOI
ScienceOn
|
12 |
Parkin DM, Bray FI, Devesa S, et al (2001). Cancer burden in the year 2000. The global picture. Eur J Cancer, 37, S4-66.
|
13 |
Kumar V, Jayasuryan N, Kumar R (1996). A truncated mutant (residues 58-140) of the hepatitis B virus X protein retains transactivation function. ProcNatl Acad Sci USA, 93, 5647-52.
DOI
|
14 |
Lee H, Kim HT, Yun Y, et al (1998). Liver-specific enhancer II is the target for the p53-mediated inhibition of hepatitis B viral gene expression. J Biol Chem, 273, 19786-91.
DOI
ScienceOn
|
15 |
Liu S, Zhang H, Gu C, et al (2009). Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst, 101, 1066-82.
DOI
ScienceOn
|
16 |
Qu LS, Liu TT, Jin F, et al (2011). Combined pre-S deletion and core promoter mutations related to hepatocellular carcinoma: A nested case-control study in China. Hepatol Res, 41, 54-63.
DOI
ScienceOn
|
17 |
Sakamoto T, Tanaka Y, Orito E, et al (2006). Novel subtypes (subgenotypes) of hepatitis B virus genotypes B and C among chronic liver disease patients in the Philippines. J Gen Virol, 87, 1873-82.
DOI
ScienceOn
|
18 |
Sakurai M, Sugauchi F, Tsai N, et al (2004). Genotype and phylogenetic characterization of hepatitis B virus among multi-ethnic cohort in Hawaii. World J Gastroenterol, 10, 2218-22.
|
19 |
Sherman M (2010). Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis, 30, 3-16.
DOI
ScienceOn
|
20 |
Shinkai N, Tanaka Y, Ito K, et al (2007). Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2. J Clin Microbiol, 45, 3191-7.
DOI
ScienceOn
|
21 |
Tangkijvanich P, Sa-Nguanmoo P, Mahachai V, et al (2010). A case-control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma. Hepatol Int, 4, 577-84.
DOI
ScienceOn
|
22 |
Sirma H, Giannini C, Poussin K, et al (1999). Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. Oncogene, 18, 4848-9.
DOI
ScienceOn
|
23 |
Stemler M, Weimer T, Tu ZX, et al (1990). Mapping of B-cell epitopes of the human hepatitis B virus X protein. J Virol, 64, 2802-9.
|
24 |
Tanaka Y, Mukaide M, Orito E, et al (2006). Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. J Hepatol, 45, 646-53.
DOI
ScienceOn
|
25 |
Tatsukawa M, Takaki A, Shiraha H, et al (2011). Hepatitis B virus core promoter mutations G1613A and C1653T are significantly associated with hepatocellular carcinoma in genotype C HBV-infected patients. BMC Cancer, 11, 458.
DOI
|
26 |
Wang Z, Tanaka Y, Huang Y, et al (2007). Clinical and virological characteristics of hepatitis B virus subgenotypes Ba, C1, and C2 in China. J Clin Microbiol, 45, 1491-6.
DOI
ScienceOn
|
27 |
Welschinger R, Kew MC, Viana R, et al (2010). T1653 mutation in the enhancer II region of the hepatitis B virus genome in southern African Blacks with hepatocellular carcinoma. Eur J Gastroenterol Hepatol, 22, 541-5.
DOI
|
28 |
Yuan J, Zhou B, Tanaka Y, et al (2007). Hepatitis B virus (HBV) genotypes/subgenotypes in China: mutations in core promoter and precore/core and their clinical implications. J Clin Virol, 39, 87-93.
DOI
ScienceOn
|
29 |
Yuen MF, Tanaka Y, Shinhai N, et al (2008). Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C,specific mutations of enhancer II/core. Gut, 57, 98-102.
|
30 |
Zhang KY, Imazeki F, Fukai K, et al (2007). Analysis of the complete hepatitis B virus genome in patients with genotype C chronic hepatitis and hepatocellular carcinoma. Cancer Sci, 98, 1921-9.
DOI
ScienceOn
|
31 |
Zhu Y, Jin Y, Guo X, et al (2010). Comparison study on the complete sequence of hepatitis B virus identifies new mutations in core gene associated with hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev, 19, 2623-30.
DOI
ScienceOn
|